
    
      The study objective is to determine if the administration of direct acting antivirals for
      12-16 weeks after kidney transplantation prevents the spread of HCV infection from donor
      kidney with known HCV infection (all genotypes) to an HCV negative recipient as evidenced by
      a negative HCV viral RNA at 12 weeks post treatment.
    
  